LIVERPOOL (MedPage Today) -- The comparable efficacy of subcutaneous tocilizumab (Actemra) and the intravenous formulation in patients with rheumatoid arthritis persisted for a year, with safety also being similar, a researcher reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment